Captopril
- CAS No.
- 62571-86-2
- Chemical Name:
- Captopril
- Synonyms
- on;(2S)-1-[(2S)-3-Mercapto-2-methylpropionyl]-2-pyrrolidinecarboxylic acid;capoten;Captopril API;Captopril-13C5;1-[(S)-3-Mercapto-2-methylpropionyl]-L-proline;Captopril,N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline;A333;sa333;lopril
- CBNumber:
- CB6206769
- Molecular Formula:
- C9H15NO3S
- Molecular Weight:
- 217.29
- MOL File:
- 62571-86-2.mol
- MSDS File:
- SDS
- Modify Date:
- 2025/3/27 21:41:50
| Melting point | 104-108 °C (lit.) |
|---|---|
| Boiling point | 427.0±40.0 °C(Predicted) |
| alpha | -129.5 º (c=1, EtOH) |
| Density | 1.2447 (rough estimate) |
| refractive index | -127.5 ° (C=1.7, EtOH) |
| storage temp. | room temp |
| solubility | H2O: 0.1 g/mL, very slightly hazy, colorless |
| form | Crystalline Powder |
| pka | 3.7, 9.8(at 25℃) |
| color | white to off-white |
| biological source | synthetic (organic) |
| Water Solubility | soluble |
| Merck | 14,1774 |
| BRN | 477887 |
| BCS Class | 3 |
| Stability | Stable. Incompatible with strong oxidizing agents. |
| CAS DataBase Reference | 62571-86-2(CAS DataBase Reference) |
| NIST Chemistry Reference | Captopril(62571-86-2) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS08 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H341-H360F | |||||||||
| Precautionary statements | P201-P308+P313 | |||||||||
| Hazard Codes | Xn,Xi | |||||||||
| Risk Statements | 43-63-36/37/38-40 | |||||||||
| Safety Statements | 36/37-37/39-26-36-22 | |||||||||
| WGK Germany | 2 | |||||||||
| RTECS | UY0550000 | |||||||||
| HS Code | 29339900 | |||||||||
| Hazardous Substances Data | 62571-86-2(Hazardous Substances Data) | |||||||||
| Toxicity | LD50 in mice (mg/kg): 1040 i.v.; 6000 orally (Keim) | |||||||||
| NFPA 704 |
|
Captopril price More Price(11)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | C8856 | Captopril meets USP testing specifications | 62571-86-2 | 1G | ₹7480.08 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | PHR1307 | Captopril Pharmaceutical Secondary Standard; Certified Reference Material | 62571-86-2 | 1G | ₹8107.93 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | C8856 | Captopril meets USP testing specifications | 62571-86-2 | 5G | ₹18803.03 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | C8856 | Captopril meets USP testing specifications | 62571-86-2 | 25G | ₹63261.3 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | C4042 | Captopril ≥98% (HPLC), powder | 62571-86-2 | 5G | ₹22169.6 | 2022-06-14 | Buy |
Captopril Chemical Properties,Uses,Production
Description
Captopril is the most studied of the angiotensin-converting enzyme inhibitors proposed as an antihypertensive drug. It blocks angiotensin-converting enzyme, which suppresses formation of angiotensin II and relieves its vasoconstricting effect on arterial and venous vessels. Overall vascular peripheral tension is reduced, which results in the lowering of arterial pressure.
Chemical Properties
White or almost white, crystalline powder.
Uses
Captopril has also been shown to inhibit the formation of angiotensin II, a bioactive peptide that stimulates angiogenesis and increases microvessel density. Captopril demonstrates noncompetitive inhibition of tyrosinase monophenolase activity and competitive inhibition of diphenolase activity
Definition
ChEBI: A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.
Biological Functions
Captopril (Capoten) is an orally effective ACE inhibitor with a sulfhydryl moiety that is used in binding to the active site of the enzyme. Captopril blocks the blood pressure responses caused by the administration of angiotensin I and decreases plasma and tissue levels of angiotensin II.
General Description
Captopril, 1-[(2S)-3-mercapto-2-methyl-1-oxopropionyl]proline (Capoten), blocks the conversion of angiotensinI to angiotensin II by inhibiting the convertingenzyme. The rational development of captopril as an inhibitorof ACE was based on the hypothesis that ACE and carboxypeptidaseA functioned by similar mechanisms. It wasnoted that d-2-benzylsuccinic acid was a potent inhibitor ofcarboxypeptidase A, but not ACE. By use of this small molecule as a prototype, captopril was designed with a carboxylgroup on a proline and a thiol group was introduced toenhance the binding to the zinc ion of ACE. The importantbinding points at the active site of ACE are thought to be anarginine residue, which provides a cationic site that attracts acarboxylate ion, and a zinc ion, which can polarize a carbonylgroup of an amide function to make it more susceptible to hydrolysis.Hydrophobic pockets lie between these groups in theactive site, as does a functional group that forms a hydrogenbond with an amide carbonyl.
Side effects
Approximately 10% of the patients treated with captopril report a dose-related maculopapular rash that often disappears when the dosage of captopril is reduced. Other common adverse effects are fever, a persistent dry cough (incidence as high as 39%), initial dose hypotension, and a loss of taste that may result in anorexia. These effects are reversed when drug therapy is discontinued. More serious toxicities include a 1% incidence of proteinuria and glomerulonephritis; less common are leukopenia and agranulocytosis. Since food reduces the bioavailability of captopril by 30 to 40%, administration of the drug an hour before meals is recommended. All converting enzyme inhibitors are contraindicated in patients with bilateral renal artery disease or with unilateral renal artery disease and one kidney. Use under these circumstances may result in renal failure or paradoxical malignant hypertension.
Metabolism
The onset of action following oral administration of captopril is about 15 minutes, with peak blood levels achieved in 30 to 60 minutes. Its apparent biological half-life is approximately 2 hours, with its antihypertensive effects observed for 6 to 10 hours. The kidneys appear to play a major role in the inactivation of captopril.
Purification Methods
Purify it by recrystallisation from EtOAc/hexane. It is also purified by dissolving in EtOAc and chromatographed on a column of Wakogel C200 using a linear gradient of MeOH in EtOAc (0-100o) and fractions which give a positive nitroprusside test (for SH), are combined, evaporated and recrystallised from EtOAc/hexane (1:1), to give white crystals with [] D -128.2o (c 2.0, EtOH). [Nam J Pharm Sci 73 1843 1984]. Alternatively, dissolve it in H2O, apply to a column of AG-50Wx2 (BioRad) and elute with H2O. The free acid is converted to the dicyclohexylamine salt in MeCN by addition of the amine until the pH is 8-9. The salt is converted to the free acid by shaking with EtOAc and 10% aqueous KHSO4 or passage through an AG50Wx2 column. The EtOAc solution is dried (MgSO4), evaporated to dryness and the residue is recrystallised as above from EtOAc/hexane [Cushman et al. Biochemistry 16 5484 1977, NMR and IR: Horii & Watanabe Yakugaku Zasshi (J Pharm Soc Japan) 81 1786 1961]. It is an antihypertensive because it is a potent competitive inhibitor of the angiotensive convertive enzyme (ACE-inhibitor) with a Ki value of 0.0017\M [Shimazaki et al. Chem Pharm Bull Jpn 30 3139 1982].
Captopril Preparation Products And Raw materials
Raw materials
1of4
chevron_rightPreparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Medi Pharma Drug House | +919930911911 | Mumbai, India | 143 | 58 | Inquiry |
| Otto Chemie Pvt Ltd | +91-2222070099 +91-2266382599 | Maharashtra, India | 429 | 58 | Inquiry |
| Otto Chemie Pvt. Ltd. | +91 9820041841 | Mumbai, India | 5870 | 58 | Inquiry |
| TCI Chemicals (India) Pvt. Ltd. | 1800 425 7889 | New Delhi, India | 6768 | 58 | Inquiry |
| Alfa Aesar | 1 800 209 7001 | Maharashtra, India | 6905 | 58 | Inquiry |
| SynZeal Research Pvt Ltd | +1 226-802-2078 | Gujarat, India | 6514 | 58 | Inquiry |
| Triveni chemicals | 08048762458 | New Delhi, India | 6088 | 58 | Inquiry |
| Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6739 | 58 | Inquiry |
| Angle Biopharma | 08046067501 | Ahmedabad, India | 142 | 58 | Inquiry |
| Wockhardt | 09881062557 | Mumbai, India | 10 | 58 | Inquiry |
| Supplier | Advantage |
|---|---|
| Medi Pharma Drug House | 58 |
| Otto Chemie Pvt Ltd | 58 |
| Otto Chemie Pvt. Ltd. | 58 |
| TCI Chemicals (India) Pvt. Ltd. | 58 |
| Alfa Aesar | 58 |
| SynZeal Research Pvt Ltd | 58 |
| Triveni chemicals | 58 |
| Pharmaffiliates Analytics and Synthetics P. Ltd | 58 |
| Angle Biopharma | 58 |
| Wockhardt | 58 |
62571-86-2(Captopril)Related Search:
1of4
chevron_right